The stock of Cohen & Steers Clsd-End Optuny Fnd, Inc. (NYSE:FOF) is a huge mover today! About 80,635 shares traded hands. Cohen & Steers Clsd-End Optuny Fnd, Inc. (NYSE:FOF) has risen 4.95% since April 27, 2016 and is uptrending. It has underperformed by 0.28% the S&P500.
The move comes after 7 months negative chart setup for the $322.02 million company. It was reported on Nov, 30 by Barchart.com. We have $11.50 PT which if reached, will make NYSE:FOF worth $9.66 million less.
Analysts await Cohen & Steers Clsd-End Optuny Fnd, Inc. (NYSE:FOF) to report earnings on February, 8. After $-0.28 actual EPS reported by Cohen & Steers Clsd-End Optuny Fnd, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
According to Zacks Investment Research, “Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.”
Another recent and important Cohen & Steers Clsd-End Optuny Fnd, Inc. (NYSE:FOF) news was published by Reuters.com which published an article titled: “Cohen & Steers Closed-End Opportunity Fund, Inc. declare march 2015 quarterly distributions” on March 09, 2015.
FOF Company Profile
Cohen & Steers Closed-End Opportunity Fund, Inc. (the Fund), incorporated on September 14, 2006, is a diversified closed-end management investment company. The Fund’s investment objective is to achieve high total return consisting of high current income and capital appreciation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.